Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Plasmic and Plasic Αre Εxcellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes

Blood (2019) 134 (Supplement_1): 4913.

https://doi.org/10.1182/blood-2019-125343

Published: 2019

Journal Articles

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Blood (2018) 132 (Supplement 1): 3295.

https://doi.org/10.1182/blood-2018-99-114106

Published: 2018

Journal Articles

Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome

Argiris Symeonidis, MD PhD, Alexandra Kourakli, MD, Ioannis Kotsianidis, MD PhD, Panagiotis Zikos, Eleftheria Hatzimichael, Theodoros Vassilakopoulos, MDPhD, Aikaterini Palla, Vassiliki Pappa, MD, Evgenia Verigou, Zafeirios Kartasis, MD, Eirini Katodritou, Maria Pagoni, Theodora Assimakopoulou, Charalampos Pontikoglou, MD PhD, Maria Dimou, George Xanthopoulidis, Maria K. Angelopoulou, MD, Maria Kotsopoulou, Dimitra Liapi, Despina Mparmparousi, Evridiki Michali, Anna Kioumi, Nora-Athina Viniou, Achilles Anagnostopoulos, Vassiliki Labropoulou, Maria Dalekou, Michael Voulgarelis, MD PhD, Efthymia Vlachaki, Anna Christoforidou, Ioannis Adamopoulos, MD, Akrivi Kostourou, Petros Laos, Evangelos Terpos, MD PhD, Eleni Kapsali, George Vassilopoulos, MD PhD, Helen A. Papadaki, MD PhD, Panayiotis Panayiotidis, MD PhD, Athanasios Galanopoulos, MD PhD

Blood (2017) 130 (Supplement 1): 1696.

https://doi.org/10.1182/blood.V130.Suppl_1.1696.1696

Published: 2017

Journal Articles

CLLU1 Expression Is Not Confined to Chronic Lymphocytic Leukemia Cells; Putative Role of Gene-Body Hypomethylation in Regulating Splice Variant-Specific Transcriptional Dynamics

Spyros Ioannis Papamichos, MD PhD, Eleftheria Lamprianidou, Chryssoula Kordella, Anna Christoforidou, Zoe Bezirgiannidou, Ioannis Kotsianidis, PhD

Blood (2017) 130 (Supplement 1): 4979.

https://doi.org/10.1182/blood.V130.Suppl_1.4979.4979

Published: 2017

Journal Articles

Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients

Blood (2014) 124 (21): 2113.

https://doi.org/10.1182/blood.V124.21.2113.2113

Published: 2014

Journal Articles

Multiple Myeloma Patients ≤40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents

Argiris S. Symeonidis, Efstathios Kastritis, Sosana Delimpasi, Charikleia Kelaidi, Anastasia Sioni, Michalis Michael, Amalia Vassou, Anna Christoforidou, Panagiotis Repousis, Eudokia M. Mandala, Evangelos Terpos, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3226.

https://doi.org/10.1182/blood.V122.21.3226.3226

Published: 2013

Journal Articles

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Blood (2013) 122 (21): 1866.

https://doi.org/10.1182/blood.V122.21.1866.1866

Published: 2013

Journal Articles

Rituximab Is Highly Effective In The Treatment Of Patients With Autoimmune Blood Cytopenias, Particularly When It Is Followed By a Post-Induction Consolidation / Maintenance Phase

Argiris Symeonidis, MD, PhD, Nikolaos Giannakoulas, Eleni Kapsali, Anna Christoforidou, Zoe Topouzoglou, Polyxeni Lampropoulou, MD, Evangelia Tzouvara, Nikolaos Anagnostopoulos, MD, Dimitris Margaritis, George Vassilopoulos, MD, PhD, Evangelos Briasoulis, Alexandra Kouraklis

Blood (2013) 122 (21): 3539.

https://doi.org/10.1182/blood.V122.21.3539.3539

Published: 2013

Journal Articles

Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients

Blood (2013) 122 (21): 3130.

https://doi.org/10.1182/blood.V122.21.3130.3130

Published: 2013

Journal Articles

The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD Regimen) as Front-Line Therapy In Newly Diagnosed, High-Risk Multiple Myeloma: Results of a Phase II Prospective Multicenter Study

Ioannis Baltathakis, Evangelos Terpos, Sosana Delimpasi, Konstantinos Liapis, Fotios Panitsas, Efstathios Kastritis, Anna Christoforidou, Anastasia Pouli, Konstantinos Tsatalas, Meletios A. Dimopoulos, Nikolaos Harhalakis

Blood (2010) 116 (21): 3052.

https://doi.org/10.1182/blood.V116.21.3052.3052

Published: 2010

Journal Articles

Dynamics of Telomere Length and Telomerase Activity in Ph 1 -Negative Chronic Myeloproliferative Disorders

Ioanna Bazdiara, Despina Pantelidou, Athanasios Anastasiadis, Vassilios Papadopoulos, Dimitrios Margaritis, Emmanouil Spanoudakis, Georgios Xanthopoulidis, Ioannis Kotsianidis, Anna Christoforidou, Aggelos Goutzouvelidis, Georgios Bourikas, Konstantinos Tsatalas

Blood (2008) 112 (11): 2789.

https://doi.org/10.1182/blood.V112.11.2789.2789

Published: 2008

Journal Articles

The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.

Evangelos Terpos, Sosana Delimpasi, Konstantinos Anargyrou, Ioannis Baltathakis, Efstathios Kastritis, Anna Christoforidou, Konstantinos Tsionos, Konstantinos Tsatalas, Emmanuel Nikiforakis, Meletios A. Dimopoulos, Nikolaos Harhalakis

Blood (2007) 110 (11): 3596.

https://doi.org/10.1182/blood.V110.11.3596.3596

Published: 2007

Journal Articles

Impact of Holmium-DOTMP on Transplant Outcomes. Results of a Retrospective Single Institution Analysis.

Anna Christoforidou, MD, Patricia Williams, RN, Linda Roden, MD, Ana Aleman, MD, Donna Weber, MD, Floralyn Mendoza, BS, Donald Podoloff, MD, Hazel Breitz, MD, Raymond Alexanian, MD, Richard Champlin, MD, Sergio Giralt, MD

Blood (2005) 106 (11): 426.

https://doi.org/10.1182/blood.V106.11.426.426

Published: 2005

NARROW

Plasmic and Plasic Αre Εxcellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome

CLLU1 Expression Is Not Confined to Chronic Lymphocytic Leukemia Cells; Putative Role of Gene-Body Hypomethylation in Regulating Splice Variant-Specific Transcriptional Dynamics

Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients

Multiple Myeloma Patients ≤40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Rituximab Is Highly Effective In The Treatment Of Patients With Autoimmune Blood Cytopenias, Particularly When It Is Followed By a Post-Induction Consolidation / Maintenance Phase

Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients

The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD Regimen) as Front-Line Therapy In Newly Diagnosed, High-Risk Multiple Myeloma: Results of a Phase II Prospective Multicenter Study

Dynamics of Telomere Length and Telomerase Activity in Ph 1 -Negative Chronic Myeloproliferative Disorders

The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.

Impact of Holmium-DOTMP on Transplant Outcomes. Results of a Retrospective Single Institution Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only